Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine is a Subunit Vaccine owned by Merck & Co, and is involved in 67 clinical trials, of which 61 were completed, 4 are ongoing, and 2 are planned.

Gardasil has highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. The efficacy of LI VLP vaccines is mediated by the development of a humoral immune response.

The revenue for Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine is expected to reach a total of $191.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine NPV Report.

Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine is currently owned by Merck & Co.

Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine Overview

Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard) is an adjuvant non-infectious recombinant quadrivalent vaccine acts as immunizing preparation against human papillomavirus. L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology. It is formulated as suspension for injection administered by intramuscular route. It is a vaccine for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer causally related to certain oncogenic Human Papillomavirus (HPV) types and for treatment of genital warts (condyloma acuminata) causally related to specific HPV types. Gardasil indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: cervical, vulvar, vaginal and anal cancer caused by HPV types 16 and 18, genital warts (con dyloma acuminata) caused by HPV types 6 and 11 nd the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 1, vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3, vginal intraepithelial neoplasia (VaIN) grade 2 and grade 3, anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. Gardasil is indicated in boys and men 9 through 26 years of age for the prevention of  the following  diseases caused by HPV types included in the vaccine: anal cancer caused by HPV types 16 and 18, genital warts (condyloma acuminata) caused by HPV types 6 and 11 and the following precancerous o r dysplastic lesions caused by HPV types 6, 11, 16, and 18, anal  intraepithelial neoplasia (AIN) grades 1, 2, and 3.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine

Report Segments
  • Innovator (NME)
Drug Name
  • Human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
  • Oncology
  • Women’s Health
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.